105 related articles for article (PubMed ID: 21276592)
1. Genetics of the coenzyme Q10 pathway and rosuvastatin-induced muscle effects.
Puccetti L; Scarpini F; Auteri A; Ciani F
J Pediatr; 2011 Mar; 158(3):520-1. PubMed ID: 21276592
[No Abstract] [Full Text] [Related]
2. Rosuvastatin lowers coenzyme Q10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia.
Avis HJ; Hargreaves IP; Ruiter JP; Land JM; Wanders RJ; Wijburg FA
J Pediatr; 2011 Mar; 158(3):458-62. PubMed ID: 20884007
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease.
Toyama K; Sugiyama S; Oka H; Iwasaki Y; Sumida H; Tanaka T; Tayama S; Jinnouchi H; Matsui K; Ogawa H
Atherosclerosis; 2011 Jul; 217(1):158-64. PubMed ID: 21458815
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Gazi I; Kostara C; Bairaktari ET; Elisaf M
J Clin Pharmacol; 2006 Nov; 46(11):1337-43. PubMed ID: 17050799
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin calcium.
Quirk J; Thornton M; Kirkpatrick P
Nat Rev Drug Discov; 2003 Oct; 2(10):769-70. PubMed ID: 14579811
[No Abstract] [Full Text] [Related]
6. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
Landsberger M; Jantzen F; Könemann S; Felix SB
Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
[TBL] [Abstract][Full Text] [Related]
7. Does rosuvastatin offer therapeutic potential in autoimmune thyroiditis in nonobese diabetic mice?
Mori K; Nakagawa Y; Hoshikawa S; Ozaki H; Ito S; Yoshida K
Clin Immunol; 2009 Mar; 130(3):375-7. PubMed ID: 19019736
[No Abstract] [Full Text] [Related]
8. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
Qin S; Koga T; Ganji SH; Kamanna VS; Kashyap ML
Metabolism; 2008 Jul; 57(7):973-9. PubMed ID: 18555840
[TBL] [Abstract][Full Text] [Related]
9. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin.
Ajith TA; Riji T; Anu V
Clin Exp Pharmacol Physiol; 2008 May; 35(5-6):625-9. PubMed ID: 18177480
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
[TBL] [Abstract][Full Text] [Related]
11. Coenzyme Q10 and statins in heart failure: the dog that didn't bark.
Felker GM
J Am Coll Cardiol; 2010 Oct; 56(15):1205-6. PubMed ID: 20883927
[No Abstract] [Full Text] [Related]
12. Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis.
Chan KL; Dumesnil JG; Tam J; Ni A; Teo K
Am Heart J; 2011 Jun; 161(6):1133-9. PubMed ID: 21641360
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
Kang BY; Mehta JL
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
[TBL] [Abstract][Full Text] [Related]
14. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells.
Kim YS; Ahn Y; Hong MH; Kim KH; Park HW; Hong YJ; Kim JH; Kim W; Jeong MH; Cho JG; Park JC; Kang JC
J Cardiovasc Pharmacol; 2007 Jun; 49(6):376-83. PubMed ID: 17577102
[TBL] [Abstract][Full Text] [Related]
16. [Rosuvastatin: pharmacologic features].
Bernini F; Catapano AL
Ital Heart J; 2003 Dec; 4 Suppl 7():22S-32S. PubMed ID: 14983744
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
[TBL] [Abstract][Full Text] [Related]
18. Coenzyme Q10 and statin-related myopathy.
Drug Ther Bull; 2015 May; 53(5):54-6. PubMed ID: 25977402
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat.
van der Harst P; Groenewegen HC; Roks AJ; Buikema H; Zijlstra F; van Gilst WH; de Smet BJ
Coron Artery Dis; 2008 Feb; 19(1):47-53. PubMed ID: 18281816
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosenson RS
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
